R/epileptic.qol.R

In joineRML: Joint Modelling of Multivariate Longitudinal Data and Time-to-Event Outcomes

#' Quality of life data following epilepsy drug treatment
#'
#' @description The SANAD (Standard and New Antiepileptic Drugs) study (Marson
#'   et al., 2007) is a randomised control trial of standard and new
#'   antiepileptic drugs, comparing effects on longer term clinical outcomes.
#'   Quality of life (QoL) data were collected by mail at baseline, 3 months,
#'   and at 1 and 2 years using validated measures. This data is a subset of the
#'   trial for 544 patients randomised to one of 2 drugs: carbamazepine and
#'   lamotrigine.
#'
#' @usage data(epileptic.qol)
#' @format A data frame with 1853 observations on the following 9 variables:
#'   \describe{
#'
#'   \item{\code{id}}{patients identifier; in total there are 544 patients.}
#'
#'   \item{\code{with.time}}{number of days between registration and the earlier
#'   of treatment failure or study analysis time.}
#'
#'   \item{\code{trt}}{a factor with levels \code{CBZ} and \code{LTG} denoting
#'   carbamazepine and lamotrigine, respectively.}
#'
#'   \item{\code{with.status}}{the reason for treatment failure. Coded as
#'   \code{0=}censored; \code{1=}unacceptable adverse effects;
#'   \code{2=}inadequate seizure control.}
#'
#'   \item{\code{time}}{the time the quality of life measures were recorded
#'   (days). The first measurement for each subject is the baseline measurement,
#'   however there was variability between the time taken to return the
#'   questionnaires; hence the reason this is non-zero. Similarly, the second,
#'   third, and fourth follow-up times, which were scheduled for 3-months,
#'   1-year, and 2-years, respectively, also had variability in completion
#'   times.}
#'
#'   \item{\code{anxiety}}{a continuous measure of anxiety, as defined according
#'   to the NEWQOL (Newly Diagnosed Epilepsy Quality of Life) assessment. Higher
#'   scores are indicative of worse QoL.}
#'
#'   \item{\code{depress}}{a continuous measure of depression, as defined
#'   according to the NEWQOL (Newly Diagnosed Epilepsy Quality of Life)
#'   assessment. Higher scores are indicative of worse QoL.}
#'
#'   \item{\code{aep}}{a continuous measure of the Liverpool Adverse Events
#'   Profile (AEP), as defined according to the NEWQOL (Newly Diagnosed Epilepsy
#'   Quality of Life) assessment. Higher scores are indicative of worse QoL.}
#'
#'   \item{\code{with.status2}}{a binary indicator of composite treatment
#'   failure (for any reason), coded \code{status2=1}, or right-censoring
#'   \code{status2=0}.}
#'
#'   }
#' @keywords datasets
#' @seealso \code{\link{pbc2}}, \code{\link{heart.valve}}, \code{\link{renal}}.
#' @source SANAD Trial: University of Liverpool. See Jacoby et al. (2015).
#'
#' @references
#'
#' Jacoby A, Sudell M, Tudur Smith C, et al. Quality-of-life outcomes of
#' initiating treatment with standard and newer antiepileptic drugs in adults
#' with new-onset epilepsy: Findings from the SANAD trial. \emph{Epilepsia}.
#' 2015; \strong{56(3)}: 460-472.
#'
#' Marson AG, Appleton R, Baker GA, et al. A randomised controlled trial
#' examining longer-term outcomes of standard versus new antiepileptic drugs.
#' The SANAD Trial. \emph{Health Technology Assessment}. 2007; \strong{11(37)}.
#'
#' Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness
#' of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for
#' treatment of partial epilepsy: an unblinded randomised controlled trial.
#' \emph{Lancet}. 2007; \strong{365}: 2007-2013.
#'
#' Abetz L, Jacoby A, Baker GA, et al. Patient-based assessments of quality of
#' life in newly diagnosed epilepsy patients: validation of the NEWQOL.
#' \emph{Epilepsia}. 2000; \strong{41}: 1119-1128.
"epileptic.qol"